EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tangeretin suppresses HER2-driven breast cancer via PI3K/AKT/mTOR inhibition and caspase-dependent apoptosis

Jaggareddygari Shruthi Reddy, Puligilla Shankaraiah

Bangladesh Journal of Pharmacology · 02.03.2026 · 21 (1) · 1-10

DOI: 10.3329/bjp.v21i1.85717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bangladesh Journal of Pharmacology, online erschienen am 02.03.2026. Verfasst von Jaggareddygari Shruthi Reddy und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tangeretin, a citrus-derived polymethoxylated flavone, exhibits potent and selective anti-cancer activity against HER2-positive breast cancer. It demonstrated cytotoxicity in SKBR3 cells (IC₅₀ = 19.5 ± 1.7 µM) and MCF-7 cells (IC₅₀ = 36.2 ± 2.4 µM), while sparing non-tumorigenic MCF-10A cells (>90% viability; IC₅₀ = 327.5 ± 18.2 µM). Tangeretin markedly reduced clonogenic survival (51.4 ± 3.1 colonies in SKBR3; 78.1 ± 3.7 in MCF-7) and induced pronounced apoptosis, as evidenced by late apoptotic staining (50.6 ± 2.3%), DNA laddering, and strong activation of caspase-3/7 (3.4 ± 0.1-fold) and caspase-9 (2.9 ± 0.1-fold). Flow cytometry revealed significant G₂/M phase arrest in SKBR3 cells (38.9 ± 2.0%). Mechanistically, tangeretin suppressed AKT kinase activity (0.4 ± 0.04-fold), comparable to MK-2206 (0.3 ± 0.0-fold), and reduced the expression of phosphorylated HER2 (p-HER2), p-PI3K, p-AKT, p-mTOR, p-p70S6K, and cyclin D1. These findings establish tangeretin as a selective HER2-targeted anti-cancer candidate that acts through dual inhibition of the PI3K/AKT/mTOR pathway and induction of mitochondrial apoptosis.

Zitieren

APA

Reddy, J. S., & Shankaraiah, P. (2026). Tangeretin suppresses HER2-driven breast cancer via PI3K/AKT/mTOR inhibition and caspase-dependent apoptosis. Bangladesh Journal of Pharmacology, 21(1), 1-10. https://doi.org/10.3329/bjp.v21i1.85717

Vancouver

Reddy JS, Shankaraiah P. Tangeretin suppresses HER2-driven breast cancer via PI3K/AKT/mTOR inhibition and caspase-dependent apoptosis. Bangladesh Journal of Pharmacology. 2026;21(1):1-10. doi:10.3329/bjp.v21i1.85717

BibTeX
@article{Reddy2026,
  author = {Reddy, Jaggareddygari Shruthi and Shankaraiah, Puligilla},
  title = {Tangeretin suppresses HER2-driven breast cancer via PI3K/AKT/mTOR inhibition and caspase-dependent apoptosis},
  journal = {Bangladesh Journal of Pharmacology},
  year = {2026},
  volume = {21},
  number = {1},
  pages = {1--10},
  doi = {10.3329/bjp.v21i1.85717}
}
Kostenlos starten →